

CXCR4

Research Grade Ulocuplumab (BMS-936564 / MDX-1338)

Catalog No.	DHF39901A DHF39901B	Quantity:	100 µg 1.0 mg
Alternate Names:	C-X-C chemokine receptor type 4, CXCR4, SDF-1, CD184, BMS-936564, MDX1338		
Description:	Ulocuplumab (BMS-936564, MDX-1338) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow. CXCR4 is overexpressed in more than 23 types of human cancers and contributes to tumor growth, angiogenesis, metastasis, and therapeutic resistance. Ulocuplumab was developed for the treatment of hematologic malignancies.		
UniProt ID:	P61073		
Specificity:	Human CXCR4		
Concentration:	1.0 mg/ml, lot specific		
Source:	Mammalian cell line		
Isotype:	Humanized IgG4 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

